Chinese vaccine developer Maxvax closes Series C round with IDG-led $41m tranche

Chinese vaccine developer Maxvax closes Series C round with IDG-led $41m tranche

Photo from Maxvax's official website

03 July, 2024

Edited by: Pramod Mathew

clinical trials herpes zoster IDG Capital Maxvax Biotechnology vaccines

Printed by Unregistered user on Sun, 21 Dec 2025 16:25:46 GMT

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief

Subscribe to Newsletter

You may also like

KKR, Blackstone in race for Advent-owned Bharat Serums & Vaccines: Report

China's Fosun to buy remaining stake in Henlius Biotech, valuing drugmaker at $1.7b

Read more from Greater China

Policy & Regulations

China issues new rules to regulate internet platform pricing

Chinese humanoid robot developer Galbot raises $300m at $3b valuation